1. INTRODUCTION
1.1. Market Definition
1.2. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Force Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. NORTH AMERICA ANTIBODY-DRUG CONJUGATES MARKET, BY PRODUCT TYPE
5.1. Introduction
5.2. Adcetris
5.3. Kadcyla
5.4. Other Product Types
6. NORTH AMERICA ANTIBODY-DRUG CONJUGATES MARKET, BY APPLICATION
6.1. Introduction
6.2. Breast Cancer
6.3. Blood Cancer
6.4. Ovarian Cancer
6.5. Lung Cancer
6.6. Brain Tumor
6.7. Others
7. NORTH AMERICA ANTIBODY-DRUG CONJUGATES MARKET, BY END-USER
7.1. Introduction
7.2. Hospitals
7.3. Clinics
7.4. Others
8. NORTH AMERICA ANTIBODY-DRUG CONJUGATES MARKET, BY GEOGRAPHY
8.1. Introduction
8.2. United States
8.3. Canada
8.4. Mexico
9. COMPETITIVE INTELLIGENCE
9.1. Major Players and Strategy Analysis
9.2. Emerging Players and Market Lucrative
9.3. Mergers, Acquisition, Agreements, and Collaborations
9.4. Vendor Competitiveness Matrix
10. COMPANY PROFILES
10.1. GlaxoSmithKline Plc
10.2. Takeda Pharmaceutical Company Ltd.
10.3. F. Hoffmann-La Roche Ltd.
10.4. Pfizer, Inc
10.5. AstraZeneca
10.6. Gilead Sciences, Inc.
10.7. Astellas Pharma
10.8. Seagen, Inc.
10.9. Seattle Genetics Inc.
10.10. Genentech Inc.
10.11. Immunogen Inc.
10.12. MabPlex USA, Inc.